19-21
March
Berlin, Germany
Presentation
Anna Chiara Giovannelli Ph.D.
Anna C. Giovannelli's presentation at the DEGRO symposium “The Future of Hyperthermia: Strategic Synergy of Hyperthermia Technologies and Software Innovations in the Context of Certification Standards” is now available.
View the detailed presentation in its entirety (PDF) Watch the video now (13 Min.)Upcoming
Events
All Events
15-19
May
Stockholm, Sweden
ESTRO 2026 – The European Society for Radiotherapy and Oncology
12
June
Erlangen, Germany
56. Hyperthermie-Arbeitstreffen des Atzelsberger Kreises
25-27
June
Leipzig, Germany
DEGRO 2026 - 32. Kongress der Deutschen Gesellschaft für Radioonkologie
17-19
September
Crans-Montanta, Switzerland
30th Annual Meeting - Scientific Association of Swiss Radiation Oncology (SASRO)
04-06
October
Erlangen, Germany
37th Annual Meeting - European Society for Hyperthermic Oncology (ESHO)
16-17
October
Baden, Austria
43. ÖGRO Jahrestagung
The HEAT trial
Prof. Dr. Issels
Pancreatic cancer: Hyperthermia trial demonstrates significantly improved post-recurrence survival
The randomized clinical trial "Hyperthermia European Adjuvant Trial" (HEAT) investigated regional hyperthermia (RHT) with cisplatin added to gemcitabine compared to chemotherapy with gemcitabine alone in the adjuvant treatment after resection of pancreatic cancer. The results show a significantly improved post-recurrence survival and a trend towards improved overall survival using Pyrexar Medical's BSD-2000 3D radiative hyperthermia system. Pancreatic cancer is one of the most common causes of cancer-related death worldwide. The HEAT trial was prematurely stopped in May 2018, when the modified FOLFIRINOX regimen replaced gemcitabine as standard therapy. The trial included a total of 117 patients with a median follow-up of 56.6 months.
